- CSR Summary Not Available
- NCT00317538
- Primary Citation
- Data Specification Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaImmune System DiseasesEnrollment28% FemaleN/A% WhiteN/A
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberC0168T61Data PartnerJohnson & JohnsonCondition StudiedArthritis, RheumatoidMean/Median Age (Years)N/A
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available